


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended): A compound of formula I



in which

R¹ is H, =O, COOR³, OH, OA, NH₂, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N₃, ethynyl, vinyl, allyloxy, -OCOR³, NHCOA or NHSO₂A,

R² is H, =O, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R¹ and R² together can also be a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R³ is H or A,

R⁴ is H or A;



is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl, thiazolidine-3,4-diyl, 2,5-dihydro-1H-pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinan-3,4-diyl, piperazine-1,4-diyl, tetrahydrafuran-3,4-diyl or azetidine-1,2-diyl,

D is phenyl, pyridyl or thiienyl, which in each case is monosubstituted or disubstituted by Hal,

G is (CH₂)_n or (CH₂)_nNH-,

X is CONH,

Y is 1,3- or 1,4-phenylene which is unsubstituted or monosubstituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,

T is morpholin-4-yl which is monosubstituted or disubstituted by carbonyl

oxygen,

A is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H atoms are each optionally replaced by F,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2;

or a pharmaceutically usable salt, or stereoisomer thereof, including mixtures thereof in all ratios.

2. (Cancelled):

3. (Cancelled):

4. (Cancelled):

5. (Cancelled):

6. (Cancelled):

7. (Cancelled):

8. (Cancelled):

9. (Cancelled):

10. (Cancelled):

11. (Cancelled):

12. (Cancelled):

13. (Cancelled):

14. (Cancelled):
15. (Cancelled):
16. (Cancelled):
17. (Cancelled):
18. (Cancelled):
19. (Cancelled):
20. (Cancelled):
21. (Cancelled):
22. (Cancelled):
23. (Currently Amended): A compound according to Claim 1, wherein said compound is selected from:
1-N-[(4-chlorophenyl)]-2-N-[[4-(3-oxomorpholin-4-yl)phenyl]]-(R)-pyrrolidine-1,2-dicarboxamide,
1-N-[(4-chlorophenyl)]-2-N-[[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]]-(R)-pyrrolidine-1,2-dicarboxamide,
1-N-[(4-chlorophenyl)]-2-N-[[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]]-(R)-pyrrolidine-1,2-dicarboxamide,
1-N-[(4-chlorophenyl)]-2-N-[[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]]-(R)-pyrrolidine-1,2-dicarboxamide,
1-N-[(4-chlorophenyl)]-2-N-[[3-trifluoromethyl-4-(3-oxomorpholin-4-yl)phenyl]]-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-piperidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-2,5-dihydropyrrole-1,2-dicarboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(R)-1-(5-chlorothiophene-2-carbonyl)pyrrolidine-2-carboxamide,

N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-(R)-1-(5-chlorothiophene-2-carbonyl)pyrrolidine-2-carboxamide,

3-N-[(4-chlorophenyl)-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-oxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)-4-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-oxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)-4-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)-4-N-{[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(4R,5R)-5-methyloxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)-4-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(S)-thiazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)-4-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(S)-1,1-dioxo-1*λ*⁶-thiazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(S)-thiazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(S)-1,1-dioxo-1*λ*⁶-thiazolidine-3,4-dicarboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-3-(5-chlorothiophene-2-carbonyl)oxazolidine-5-

carboxamide,

N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-(5-chlorothiophene-2-carbonyl)oxazolidine-5-carboxamide,

1-N-[(5-chloropyridin-2-yl)]-2-N-[[4-(3-oxomorpholin-4-yl)phenyl]]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(5-chloropyridin-2-yl)]-2-N-[[4-(3-oxomorpholin-4-yl)phenyl]]-(R)-4,4-dimethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[4-(3-oxomorpholin-4-yl)phenyl]]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]]-(2R,3R)-3-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]]-(2R,3S)-3-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[4-(3-oxomorpholin-4-yl)phenyl]]-(2R,4S)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[4-(3-oxomorpholin-4-yl)phenyl]]-(2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[4-(3-oxomorpholin-4-yl)phenyl]]-3,4-dihydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[4-(3-oxomorpholin-4-yl)phenyl]]-(2R,4S)-4-azidopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[4-(3-oxomorpholin-4-yl)phenyl]]-(2R,4S)-4-aminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[4-(3-oxomorpholin-4-yl)phenyl]]-(2R,4R)-4-azidopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[4-(3-oxomorpholin-4-yl)phenyl]]-(2R,4R)-4-aminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-acetaminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-acetaminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-methylsulfonylaminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methylsulfonylaminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-propoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-allyloxyppyrrolidine-1,2-dicarboxamide,

(3R,5R)-1-(4-chlorophenylcarbamoyl)-5-[4-(3-oxomorpholin-4-yl)-phenylcarbamoyl]pyrrolidin-3-yl isobutyrate,

(3R,5R)-1-(4-chlorophenylcarbamoyl)-5-[4-(3-oxomorpholin-4-yl)-phenylcarbamoyl]pyrrolidin-3-yl propionate,

(3R,5R)-1-(4-chlorophenylcarbamoyl)-5-[4-(3-oxomorpholin-4-yl)-phenylcarbamoyl]pyrrolidin-3-yl acetate,

4-N-[(4-chlorophenyl)-5-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-1,3-dioxolane-4,5-dicarboxamide,

4-N-[(4-chlorophenyl)-5-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-1,3-dioxolane-4,5-dicarboxamide,

4-N-[(4-chlorophenyl)-5-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-1,3-dioxolane-2,2-dimethyl-4,5-dicarboxamide,

4-N-[(4-chlorophenyl)-5-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-1,3-dioxolane-2,2-dimethyl-4,5-dicarboxamide,

1-N-[4-chlorophenyl]-2-N-[[4-(3-oxomorpholin-4-yl)phenyl]]-1-BOC-piperazine-1,2-dicarboxamide,

1-N-[4-chlorophenyl]-2-N-[[4-(3-oxomorpholin-4-yl)phenyl]]piperazine-1,2-dicarboxamide,

1-N-[4-chlorophenyl]-2-N-[[4-(3-oxomorpholin-4-yl)phenyl]]-1,3-oxazinane-3,4-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[4-(3-oxomorpholin-4-yl)phenyl]]-(2R,4S)-4-ethynyl-4-hydroxypyrrolidine-1,2-dicarboxamide,

6-N-[(4-chlorophenyl)]-7-N-[[4-(3-oxomorpholin-4-yl)phenyl]]-4-oxa-6-azaspiro[2.4]heptane-6,7-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]]-(2R,4S)-4-acetaminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[4-(3-oxomorpholin-4-yl)phenyl]]-(2R,4S)-4-butylsulfonylaminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[4-(3-oxomorpholin-4-yl)phenyl]]-(R)-4-oxypyrrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]]-(2R,4S)-4-aminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]]-(S)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[2-(4-chlorophenyl)acetyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-(4-chlorobenzoyl)-4-hydroxypyrrolidine-2-carboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]]-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]]-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-(2-methylpropanoylamino)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

2-N-[(4-chlorophenyl)-1-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

2-N-[(4-chlorophenyl)-1-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(S)-pyrrolidine-1,2-dicarboxamide,

N-(4-chlorophenyl)-(R)-1-{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl}pyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(S)-1-{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl}pyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(2R,4R)-1-{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl}-4-methoxypyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(2R,4S)-1-{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl}-4-methoxypyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(2S,4R)-1-{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl}-4-methoxypyrrolidine-2-carboxamide,

1-N-[(4-chlorophenyl)-2-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(prop-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(but-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(2,3-dihydroxypropoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(2-hydroxy-3-pyrrolidin-1-ylpropoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(2-oxooxazolidin-5-ylmethoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(3-amino-2-hydroxypropoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-2,5-dihydropyrrole-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-2,5-dihydropyrrole-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2S,3S)-3-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2S,4S)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-carboxy-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-3-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,3S,4R)-3,4-dihydroxypyrrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-allyloxyppyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(prop-2-nyloxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-(prop-2-nyloxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(methoxycarbonylmethoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(carboxymethoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-bromophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methoxypyrrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(2,3-dihydroxypropoxy)pyrrolidine-1,2-dicarboxamide,


1-N-[(4-chlorophenyl)]-2-N-[{2-aminocarbonyl-4-(3-oxomorpholin-4-yl)phenyl}]-
(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide;
1-N-[(4-chlorophenyl)]-2-N-[{4-(3-oxomorpholin-4-yl)phenyl}]-
(2R,4R)-4-hydroxy-
2-methylpyrrolidine-1,2-dicarboxamide,
1-N-[(4-chlorophenyl)]-3-N-[{4-(3-oxomorpholin-4-yl)phenyl}]piperidine-1,3-
dicarboxamide,
1-N-[(4-chlorophenyl)]-3-N-[{3-methyl-4-(3-oxomorpholin-4-yl)phenyl}]piperidine-
1,3-dicarboxamide,
1-N-[(4-chlorophenyl)]-2-N-[{4-(3-oxomorpholin-4-yl)phenyl}]-
(2R,4R)-4-(2-
methoxyethoxy)pyrrolidine-1,2-dicarboxamide,
1-N-[(4-chlorophenyl)]-2-N-[{2-methyl-4-(3-oxomorpholin-4-yl)phenyl}]-
(2R,4R)-4-
hydroxypyrrolidine-1,2-dicarboxamide,
1-N-[(4-chlorophenyl)]-2-N-[{4-(3-oxomorpholin-4-yl)phenyl}]-
(2R,4R)-4-
hydroxypyrrolidine-1,2-dicarboxamide,
1-N-[(4-chlorophenyl)]-2-N-[{2-(3-oxomorpholin-4-yl)phenyl}]-
(2R,4R)-4-
hydroxypyrrolidine-1,2-dicarboxamide,
and pharmaceutically usable salts and stereoisomers thereof, including mixtures
thereof in all ratios.

24. (Cancelled):

25. (Cancelled):

26. (Currently Amended): A process for the preparation of compounds according
to claim 1, said process comprising

a) for the preparation of compounds of the formula I in which W is N and G is
NH,
a compound of formula II



in which

R^1 , R^2 , E, X, Y and T are as defined in Claim 1, and W is N,

is reacted with a compound of formula III



III


in which

D is as defined in Claim 1,

or

b) Θ for the preparation of compounds of formula I in which W is N,

a compound of formula II



in which

R^1 , R^2 , E, X, Y and T are as defined in Claim 1, and W is N,

is reacted with a compound of formula VI



VI

in which

D and G are as defined in Claim 1, and L is Cl, Br, I or a free or reactively functionally modified OH group,

and/or

a base or acid of the formula I is converted into one of its salts.

27. (Cancelled):

28. (Cancelled):

29. (Previously Presented): A medicament composition comprising at least one compound according to claim 1 and one or more excipients and/or adjuvants.

30. (Previously Presented): A medicament composition comprising at least one compound according to claim 1 and at least one further medicament active ingredient.

31. (Previously Presented): A method for the treatment of a patient suffering from thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases, comprising administering to said patient an effective amount of a compound according to claim 1.

32. (Previously Presented): A kit comprising separate packs of:

- (a) an effective amount of a compound according to claim 1,
and
- (b) an effective amount of a further medicament active ingredient.

33. (Previously Presented): A method according to claim 31, further comprising administering to said patient at least one further medicament active ingredient.

34. (Cancelled):

35. (Cancelled):

36. (Cancelled):

37. (Cancelled):

38. (Cancelled):

39. (Cancelled):

40. (Currently Amended): A medicament composition according to Claim 30, wherein said at least one compound is 1-N-[(4-chlorophenyl)-2-N-[(4-(3-oxomorpholin-4-yl)phenyl)-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide and/or a pharmaceutically usable derivative, solvate, salt or stereoisomer thereof, including mixtures thereof in all ratios, and said at least one further medicament active ingredient is aspirin.

41. (Currently Amended): A method according to Claim 33, wherein 1-N-[(4-chlorophenyl)-2-N-[(4-(3-oxomorpholin-4-yl)phenyl)-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide and/or pharmaceutically usable derivative, solvate, salt or stereoisomer thereof, including mixtures thereof in all ratios, and aspirin are administered to said patient.

42. (Previously Presented): A compound according to claim 1, wherein



is pyrrolidine-1,2-diyil,

G is -NH-, and


X is CONH.

43. (Previously Presented): A compound according to claim 1, wherein R¹ is H, =O, COOA, OH, OA, NH₂, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N₃, ethynyl, vinyl, allyloxy, methylcarbonyloxy, acetamino, or methylsulfonylamino.


44. (Previously Presented): A compound according to claim 1, wherein R² is H, =O, OH, methoxy, or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms.

45. (Currently Amended): A compound according to claim 1, wherein R³ R⁴ is H.

46. (Previously Presented): A compound according to claim 1, wherein




47. (Previously Presented): A compound according to claim 1, wherein



48. (Previously Presented): A compound according to claim 1, wherein



49. (Previously Presented): A compound according to claim 1, wherein



50. (Previously Presented): A compound according to claim 1, wherein

 is 2,5-dihydro-1*H*-pyrrole-1,5-diyl.

51. (Previously Presented): A compound according to claim 1, wherein

 is 1,3-dioxolane-4,5-diyl.

52. (Previously Presented): A compound according to claim 1, wherein

 is 1,3-oxazinane-3,4-diyl.

53. (Previously Presented): A compound according to claim 1, wherein

 is piperazine-1,4-diyl.

54. (Previously Presented): A compound according to claim 1, wherein

 is tetrahydrofuran-3,4-diyl.

55. (Previously Presented): A compound according to claim 1, wherein

 is or azetidine-1,2-diyl.

56. (Previously Presented): A compound according to claim 1, wherein D is phenyl which is monosubstituted or disubstituted by Hal.

57. (Previously Presented): A compound according to claim 1, wherein D is

pyridyl which is monosubstituted or disubstituted by Hal.

58. (Previously Presented): A compound according to claim 1, wherein D is thiaryl which is monosubstituted or disubstituted by Hal.

59. (Previously Presented): A compound according to claim 1, wherein G is $(\text{CH}_2)_n$.

60. (Previously Presented): A compound according to claim 1, wherein G is $(\text{CH}_2)_n\text{NH}-$.

61. (New): A method according to claim 31, wherein said patient is suffering from thromboses.

62. (New): A method according to claim 31, wherein said patient is suffering from myocardial infarction.

63. (New): A method according to claim 31, wherein said patient is suffering from arteriosclerosis.

64. (New): A method according to claim 31, wherein said patient is suffering from inflammation.

65. (New): A method according to claim 31, wherein said patient is suffering from apoplexy.

66. (New): A method according to claim 31, wherein said patient is suffering from angina pectoris.

67. (New): A method according to claim 31, wherein said patient is suffering from restenosis after angioplasty.

68. (New): A method according to claim 31, wherein said patient is suffering from claudicatio intermittens.

69. (New): A method according to claim 31, wherein said patient is suffering from migraines.

70. (New): A compound according to claim 1, wherein

R¹ is H, =O, COOA, OH, OA, NH₂, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N₃, ethynyl, vinyl, allyloxy, methylcarbonyloxy, acetamino, or methylsulfonylamino;

R² is H, =O, OH, methoxy, or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms;

D is phenyl which is monosubstituted or disubstituted by Cl, pyridyl which is monosubstituted or disubstituted by Cl, or thienyl which is monosubstituted or disubstituted by Cl;

G is (CH₂)_n; and

n is 0.